CommentThe asthmas in 2015 and beyond: a Lancet Commission
References (15)
- et al.
Non-eosinophilic corticosteroid unresponsive asthma
Lancet
(1999) - et al.
Inflammometry to assess airways disease
Lancet
(2008) - et al.
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo controlled trial
Lancet
(2012) Statement by the British Thoracic Society, Research Unit of the Royal College of Physicians of London, King's Fund Centre, National Asthma Campaign
BMJ
(1990)- et al.
Why asthma still kills: the National Review of Asthma Deaths (NRAD) Confidential Enquiry report
(2014) - et al.
The definition and diagnosis of asthma
Clin Exp Allergy
(2009) - et al.
Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy
Am J Respir Crit Care Med
(2014)
Cited by (27)
A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions
2019, Value in HealthCitation Excerpt :Very few studies covered all of the items that are required for others to reproduce the results. Contemporary asthma management is shifting its focus toward identifying and treating multiple traits in patients with asthma.70 The existing decision-analytic asthma models, however, seem to lack the granularity that will be required to properly model such precision medicine approaches to asthma management.
Adrenomedullin mediates pro-angiogenic and pro-inflammatory cytokines in asthma and COPD
2019, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :Asthma and chronic obstructive pulmonary disease (COPD) are inflammatory lung diseases that cannot be cured by available drugs [1,2] and therefore, there is considerable interest to elucidate the causes and underlying mechanisms related to the systemic inflammatory processes in both diseases.
Health care costs and resource utilization for different asthma severity stages in Colombia: A claims data analysis
2018, World Allergy Organization JournalCitation Excerpt :Even though severe asthma is not common, its contribution to total costs is high [10–13]. Despite some pharmacological advances and the divulgation of guidelines for diagnosis, treatment and prevention, asthma is still a global difficult-to-treat condition and the implementation of strategies for achieving better outcomes remains heterogeneous, especially in developing countries [14–18]. In Latin America, as in other developing regions in the world, several barriers exist to achieve asthma control [19–21].
Chronic obstructive pulmonary disease subpopulations and phenotyping
2018, Journal of Allergy and Clinical ImmunologyCitation Excerpt :By enclosing different entities under the umbrella of COPD, we are committing our pathophysiologic investigations and therapeutic discoveries to fail because of multiple confounders. This is now increasingly accepted in asthmatic patients, in whom relabeling asthma and identification of treatable traits is at the forefront of current investigations.143-145 In patients with COPD, it is clear that novel endotyping approaches combined with small-airways physiologic evaluation and imaging are needed to define these different subpopulations of COPD.
Remote or in-person breathing retraining for uncontrolled asthma symptoms
2018, The Lancet Respiratory Medicine